2025/03/22 更新

写真a

スヤマ アツヒト
須山 敦仁
Atsuhito Suyama
所属
医歯薬学域 助教(特任)
職名
助教(特任)
外部リンク

学位

  • 医学博士 ( 2024年3月   岡山大学 )

研究キーワード

  • 内分泌

研究分野

  • ライフサイエンス / 代謝、内分泌学

学歴

  • 岡山大学   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences   doctoral course

    2020年4月 - 2024年3月

      詳細を見る

    国名: 日本国

    researchmap

  • 岡山大学   Medical School  

    2014年4月 - 2020年3月

      詳細を見る

    国名: 日本国

    researchmap

経歴

  • 岡山大学病院   総合内科・総合診療科   助教

    2024年10月 - 現在

      詳細を見る

  • 岡山大学病院   総合内科・総合診療科   医員

    2023年4月 - 2024年9月

      詳細を見る

  • 岡山大学   大学院医歯薬学総合研究科博士課程

    2020年4月 - 2024年3月

      詳細を見る

    国名:日本国

    researchmap

  • 岡山大学病院   卒後臨床研修センター

    2020年4月 - 2022年3月

      詳細を見る

  • 岡山大学   医学部 医学科

    2014年4月 - 2020年3月

      詳細を見る

    国名:日本国

    researchmap

 

論文

  • Is subclinical hypothyroidism associated with cardiovascular disease in the elderly? 国際誌

    Koichiro Yamamoto, Yasuhiro Nakano, Yoshiaki Soejima, Atsuhito Suyama, Kohei Oguni, Kou Hasegawa, Fumio Otsuka

    Endocrine connections   2025年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Subclinical hypothyroidism (SCH) is diagnosed when thyroid function tests show that the serum thyrotropin (TSH) level is elevated and the serum free thyroxine (FT4) level is normal. SCH is mainly caused by Hashimoto's thyroiditis, the prevalence of which increases with aging. Recently, it has been revealed that SCH is associated with risk factors for cardiovascular diseases (CVDs), including atherosclerosis, dyslipidemia and hypertension, leading to cardiovascular morbidity and mortality. However, there are still controversies regarding the diagnosis and treatment of SCH in elderly patients. In this review, we present recent evidence regarding the relationship between SCH and CVD and treatment recommendations for SCH, especially in elderly patients. Studies have shown that SCH is associated with CVD and all-cause mortality. Patients aged less than 65 years showed significant associations of SCH with CVD risk and all-cause mortality, whereas patients aged 65 or older did not show such associations. It was shown that levothyroxine therapy was associated with lower all-cause mortality and cardiovascular mortality in younger SCH patients (<65-70 years) but not in SCH patients aged 65-70 years or older. In elderly SCH patients, levothyroxine treatment should be considered individually according to the patient's age, serum TSH level, hypothyroid symptoms, CVD risk, and other comorbidities. To further elucidate the impact of SCH on CVD in elderly patients, studies should be conducted using age-specific reference ranges of results of thyroid function tests, focusing on elderly patients, specific serum TSH levels, thyroid antibody status, and cardiovascular risk factors.

    DOI: 10.1530/EC-24-0601

    PubMed

    researchmap

  • Cryptococcal prostatitis in an immunocompromised patient with tocilizumab and glucocorticoid therapy: A case report. 国際誌

    Kohei Oguni, Shinnosuke Fukushima, Hideharu Hagiya, Atsushi Kato, Atsuhito Suyama, Takehiro Iwata, Yoshia Miyawaki, Sawako Ono, Koji Iio, Fumio Otsuka

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   2024年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Cryptococcus prostatitis is an uncommon manifestation of cryptococcal infection that occurs mostly in immunocompromised patients. Tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, has been associated with an increased risk of cryptococcal infections. However, there have been no documented cases of cryptococcal prostatitis in patients receiving tocilizumab therapy. We report a case of cryptococcal prostatitis in a 72-year-old man treated with glucocorticoids and tocilizumab for giant cell arteritis and granulomatosis with polyangiitis. The patient presented dysuria and his serum level of prostate-specific antigen was elevated. Magnetic resonance imaging revealed a prostate mass, and a prostate biopsy was performed, leading to a pathologic diagnosis of cryptococcal prostatitis. Fungal cultures for blood and urine were negative, while the cryptococcal antigen for both serum and urine showed positive results. There were no particular findings in the pulmonary and central nervous systems. The patient was successfully treated with oral fluconazole (400 mg/day) and was discharged. Although cryptococcal prostatitis is a rare entity, clinicians should note that an immunosuppressed patient may develop such a difficult-to-diagnose disease.

    DOI: 10.1016/j.jiac.2024.08.009

    PubMed

    researchmap

  • Mutual Effects of Orexin and Bone Morphogenetic Proteins on Catecholamine Regulation Using Adrenomedullary Cells. 国際誌

    Yoshiaki Soejima, Nahoko Iwata, Koichiro Yamamoto, Atsuhito Suyama, Yasuhiro Nakano, Fumio Otsuka

    International journal of molecular sciences   25 ( 3 )   2024年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Orexins are neuronal peptides that play a prominent role in sleep behavior and feeding behavior in the central nervous system, though their receptors also exist in peripheral organs, including the adrenal gland. In this study, the effects of orexins on catecholamine synthesis in the rat adrenomedullary cell line PC12 were investigated by focusing on their interaction with the adrenomedullary bone morphogenetic protein (BMP)-4. Orexin A treatment reduced the mRNA levels of key enzymes for catecholamine synthesis, including tyrosine hydroxylase (Th), 3,4-dihydroxyphenylalanie decarboxylase (Ddc) and dopamine β-hydroxylase (Dbh), in a concentration-dependent manner. On the other hand, treatment with BMP-4 suppressed the expression of Th and Ddc but enhanced that of Dbh with or without co-treatment with orexin A. Of note, orexin A augmented BMP-receptor signaling detected by the phosphorylation of Smad1/5/9 through the suppression of inhibitory Smad6/7 and the upregulation of BMP type-II receptor (BMPRII). Furthermore, treatment with BMP-4 upregulated the mRNA levels of OX1R in PC12 cells. Collectively, the results indicate that orexin and BMP-4 suppress adrenomedullary catecholamine synthesis by mutually upregulating the pathway of each other in adrenomedullary cells.

    DOI: 10.3390/ijms25031585

    PubMed

    researchmap

  • Trends of correlations between serum levels of growth hormone and insulin-like growth factor-I in general practice. 国際誌

    Kohei Oguni, Koichiro Yamamoto, Yasuhiro Nakano, Yoshiaki Soejima, Atsuhito Suyama, Ryosuke Takase, Miho Yasuda, Kou Hasegawa, Fumio Otsuka

    Frontiers in endocrinology   15   1381083 - 1381083   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Serum levels of growth hormone (GH) and insulin-like growth factor (IGF)-I are crucial in the diagnosis and management of GH-related diseases. However, these levels are affected by nutritional and metabolic status. To elucidate the correlations between GH and IGF-I in various conditions, a retrospective analysis was performed for adult patients in which GH levels were examined by general practitioners during the period from January 2019 to December 2021. Of 642 patients, 33 patients were diagnosed with acromegaly, 21 were diagnosed with GH deficiency (GHD), and 588 were diagnosed with non-GH-related diseases (NGRD). In contrast to the positive correlations found between the levels of GH and IGF-I in patients with acromegaly (R=0.50; P<0.001) and patients with GHD (R=0.39; P=0.08), a negative correlation was found in the NGRD group (R=-0.23; P<0.001). In that group, the results of multivariable analysis showed that GH levels were predominantly influenced by gender and body mass index (BMI), whereas IGF-I levels were modulated by albumin in addition to age and GH. Of note, in the NGRD group, there was an enhanced negative correlation between GH and IGF-I under conditions of BMI < 22 and albumin < 4.0 g/dL (R=-0.45; P<0.001), and the negative correlation between GH and IGF-I was reinforced by excluding patients with other pituitary diseases and patients taking oral steroids (R=-0.51; P<0.001 and R=-0.59; P<0.001, respectively). Collectively, the results indicate that attention should be given to the presence of a negative correlation between serum levels of GH and IGF-I, especially in lean and low-nutritious conditions.

    DOI: 10.3389/fendo.2024.1381083

    PubMed

    researchmap

  • Functional interaction of Clock genes and bone morphogenetic proteins in the adrenal cortex 国際誌

    Yoshiaki Soejima, Koichiro Yamamoto, Yasuhiro Nakano, Atsuhito Suyama, Nahoko Iwata, Fumio Otsuka

    Vitamins and Hormones   124   429 - 447   2024年

     詳細を見る

    記述言語:英語   掲載種別:論文集(書籍)内論文   出版者・発行元:Elsevier  

    The bone morphogenetic protein (BMP) system in the adrenal cortex plays modulatory roles in the control of adrenocortical steroidogenesis. BMP-6 enhances aldosterone production by modulating angiotensin (Ang) II-mitogen-activated protein kinase (MAPK) signaling, whereas activin regulates the adrenocorticotropin (ACTH)-cAMP cascade in adrenocortical cells. A peripheral clock system in the adrenal cortex was discovered and it has been shown to have functional roles in the adjustment of adrenocortical steroidogenesis by interacting with the BMP system. It was found that follistatin, a binding protein of activin, increased Clock mRNA levels, indicating an endogenous function of activin in the regulation of Clock mRNA expression. Elucidation of the interrelationships among the circadian clock system, the BMP system and adrenocortical steroidogenesis regulated by the hypothalamic-pituitary-adrenal (HPA) axis would lead to an understanding of the pathophysiology of adrenal disorders and metabolic disorders and the establishment of better medical treatment from the viewpoint of pharmacokinetics.

    DOI: 10.1016/bs.vh.2023.05.002

    PubMed

    researchmap

▼全件表示

講演・口頭発表等

  • 低K血症・浮腫を契機に発見され、 薬物治療が奏功した高齢Cushing病の1例

    須山敦仁

    第92回 岡山内分泌同好会  2025年2月12日 

     詳細を見る

    記述言語:日本語  

    researchmap

  • 美しい自然と歴史が調和する我が故郷、倉敷市

    第38回 日本下垂体研究会学術集会  2024年8月24日 

     詳細を見る

  • 転倒後の骨折と低カリウム血症を契機に検出された高齢女性PMAHの1例

    第97回 内分泌学会学術集会  2024年6月6日 

     詳細を見る

  • 帯状疱疹の加療中に顕在化したSIADHの1例

    第33回 臨床内分泌代謝Update  2023年11月4日 

     詳細を見る

  • 多発骨折を契機に発見され、社会的介入を要したビタミンD欠乏の1例

    第96回 日本内分泌学会学術総会  2023年6月2日 

     詳細を見る

▼全件表示